Match Document Document Title
US20090053317 MICROPARTICULATE SYSTEMS FOR THE ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES  
The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins,...
US20070207958 Method of treatment of diabetes and/or obesity with reduced nausea side effect  
The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a...
US20140072558 Activin Receptor Type II B Inhibitors Comprising DLK1 Extracellular Water-Soluble Domain  
The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present...
US20110015123 Modulation of GLUT4 Gene Promoter activity BY AHNAK  
Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with...
US20100166770 ANTAGONISTS OF BACTERIAL SEQUENCES  
The present invention refers to antagonist molecules, particularly nucleic acid effector molecules directed against a bacterial RNA.
US20090093414 Hyaluronic Acid-Methotrexate Conjugate  
An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint disorders. There is provided a hyaluronic acid-methotrexate...
US20130165369 METHOD OF TREATING OBESITY AND METABOLIC DISORDERS RELATED TO EXCESS ADIPOSE TISSUE BY ADMINISTRATION OF sFRP-- PEPTIDE  
Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue,...
US20110046045 Method of treating obesity and metabolic disorders related to excess adipose tissue by administration of sFRP-5 peptide  
Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue,...
US20120322723 USE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FOR PREPARING MEDICAMENT FOR PREVENTING OR TREATING EPITHELIUM TRAUMA OF INTESTINAL MUCOSA  
The invention provides a use of the interleukin-1 receptor antagonist protein for preparing a medicament for preventing or treating epithelium trauma of the intestinal mucosa, wherein the protein...
US20080269114 Y4 Selective Receptor Agonists For Thereapeutic Interventions  
Y4 receptor agonists selective for the Y4 receptor over the Y1 and Y2 receptors are useful for treatment of conditions responsive to activation of Y4 receptors. The Y4 selective agonists (a) are...
US20140308235 METAP2 Inhibitors and Methods of Treating Obesity  
The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss,...
US20090214657 Orally Absorbed Pharmaceutical Formulation and Method of Administration  
A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound...
US20110312873 N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC  
The invention refers to multibasic, N-terminally modified tetrapeptide mimetics with a C-terminal P1-arginine mimetic, methods for their production and use for therapy and prophylaxis of diseases,...
US20090221489 Water-Soluable Films Comprising Low-Viscosity Alginates  
A film comprising as a film-forming agent an alginate salt of monovalent cation or a mixture of alginate salts containing at least one alginate salt of monovalent cation, the film-forming agent...
US20090137473 INHIBITION OF MICROTUBULE PROTRUSION IN CANCER CELLS  
The present invention generally concerns microtubule protrusions in cancer cells, including detached cancer cells, and inhibition of the protrusions. In particular aspects, the inhibition of the...
US20070135335 Therapeutic molecules  
The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals including humans. More particularly, the...
US20120251457 METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION  
Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.
US20110117049 Methods and Compositions for Modulating Adipocyte Function  
Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.
US20130196904 PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES  
The present invention refers to a pharmaceutical compositions that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled...
US20050048120 Dosage form comprising self-destructive membrane  
A sustained release dosage form is disclosed, which dosage form comprises an interior lipophilic membrane, and an exterior hydrophilic membrane comprising a peptide, that surround a composition...
US20070203061 Adiponectin expression-inducing agents and uses thereof  
The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic...
US20120108504 LEPTIN AGONIST AND METHODS OF USE  
Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance,...
US20130252884 FGF21 ANALOGUES AND DERIVATIVES  
Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in...
US20070213274 Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)  
This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in the regulation of human high density lipoprotein (HDL) and pharmaceutical...
US20100144624 PROCESS FOR THE PREPARATION OF COMPOSITIONS OF AT1 RECEPTOR ANTAGONIST AND ANGIOTENSIN-(1-7)  
We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems,...
US20050096266 Preparation and method for weight reduction  
The present invention encompasses a preparation and method whereby a trypsin inhibitor and free essential amino acids are used simultaneously in the form of an oral preparation to reduce weight.
US20140105898 APOPTOSIS-INDUCING MOLECULES AND USES THEREFOR  
This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists,...
US20090118178 Y4 SELECTIVE RECEPTOR AGONISTS FOR THERAPEUTIC INTERVENTIONS  
Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36,...
US20060205633 Therapeutic agent for diabetes  
A pharmaceutical composition herein provided comprises at least one branched chain amino acid selected from the group consisting of isoleucine, leucine and valine, combined with at least one drug...
US20100168020 STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF  
The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention...
US20100239554 EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME  
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and...
US20090155375 Compositions comprising a lipid and copolymer of styrene and maleic acid  
A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of...
US20150196617 Peptide Analogs for Treating Diseases and Disorders  
Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for...
US20060216297 Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin  
Methods and compositions are provided for reducing blood sugar levels or fat storage of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S. The...
US20140087995 Polypeptides  
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for...
US20130281363 POLYPEPTIDES  
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for...
US20070254314 Methods of treating autism and autism spectrum disorders  
The present invention relates to methods of treating a subject diagnosed with autism or an autism spectrum disorder, lowering the level of mercury in a subject determined to contain a high level...
US20090142259 Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors  
The present invention is directed to methods of diagnosing and treating, as well as articles of manufacture useful for diagnosing and treating, bladder and/or urinary tract tumor in mammals.
US20070265200 Glycol Linked Fgf-21 Compounds  
The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended...
US20100113332 METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID  
What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting...
US20130059770 POLYPEPTIDES  
The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for...
US20070128252 COMPOSITIONS AND METHODS FOR TREATMENT OF BODY WEIGHT CONDITIONS  
A nutritional supplement composition having a therapeutically effective amount of peptides is provided for the treatment of body weight conditions. The nutritional supplement may also comprise...
US20120208747 NOVEL PEPTIDE FOR AUGMENTING AND EXPRESSION OF BDNF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE OR PARKINSON'S DISEASE, COMPRISING THE SAME  
Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or...
US20130012432 Peptides for Treatment of Obesity  
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment...
US20120021973 Peptides for Treatment of Obesity  
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment...
US20100093604 Gpr43 and modulators thereof for the treatment of metabolic-related disorders  
The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is...
US20120178668 PROTEINACEOUS COMPOUNDS AND USES THEREFOR  
The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention...
US20060292186 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs  
A pharmaceutical composition in a form of an anhydrous self-nanoemulsifying oily formulation comprising: one or more therapeutic agent(s) which have low solubility in water or are water-insoluble,...
US20120178673 FAT ACCUMULATION SUPPRESSOR  
A fat accumulation suppressor comprising as an active ingredient a whey protein hydrolysate is provided. The hydrolysate has a molecular weight range of no higher than 10 kDa and a main peak of...
US20060228775 Differential expression of nucleic acid molecules  
The present invention relates generally to nucleic acid molecules expressed at least in the hypothalamus, liver, mesenteric adipose tissue, or red gastrocnemius muscle conveniently identified...